龚佳男，研究员，博士研究生导师。曾获教育部高等学校自然科学奖二等奖；获得国家自然科学基金面上项目（2025）、国家自然科学基金青年项目（2023）、北京市科技新星（2021）等项目资助。 365体育投注_365体育备用-【官方认证】@：引进人才，2020年加入365体育投注_365体育备用-【官方认证】@：。2013年11月-2020年9月在墨尔本大学生物医学系/The Walter and Eliza Hall Institute of Medical Research 医学研究所开展博士后训练。

长期从事肿瘤模型研制、癌变机理及转化应用研究。以第一或通讯作者（含共同）在Cancer Discovery、Blood (x2)、Cell Death and Differentiation（x2）等杂志发表研究型论文10余篇，授权发明专利1项。与上海华博、北京百济神州、中国医学科学院药物研究所等机构合作，利用疾病模型完成多个抗肿瘤新药和幽门螺杆菌mRNA疫苗的药效学评价。

1. Jia-Nan Gong^#*, Tirta M Djajawi, Donia M Moujalled, Giovanna Pomilio, Tiffany Khong, Li-Ping Zhang, Pasquale L Fedele, Michael S Low, Mary Ann Anderson, Christopher D Riffkin, Christine A White, Ping Lan, Guillaume Lessene, Marco J Herold, Andreas Strasser, Andrew Spencer, George Grigoriadis, Andrew H Wei, Mark F van Delft, Andrew W Roberts^* and David C Huang^*. Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro?survival BCL2 proteins. Cell Death & Differentiation. 2025; 32, 1382–1396.（IF:15.4）

2. Zhang LP, Wei YM, Luo MJ, Ren SY, Zhan XW, Wang C, Li ZF, Zhu RM, Yan S, Cheng Y, Xu JL, Yang XJ, Du KL, Wang JQ, Zhang GN, Du DX, Gao R, Zhao DB, Gong JN^*. Both direct and indirect suppression of MCL1 synergizes with BCLXL inhibition in preclinical models of gastric cancer. Cell Death & Disease. 2025;16(1):170. (IF:9.6）

3. Chao Wang, Guo-Min Xie, Li-Ping Zhang, Shuo Yan, Jia-Li Xu, Yun-Lin Han, Ming-Jie Luo, Jia-Nan Gong^*. High Engraftment and Metastatic Rates in Orthotopic Xenograft Models of Gastric Cancer via Direct Implantation of Tumor Cell Suspensions. Cancers (Basel). 2024;16(4):759. (IF:4.5)

4. Yumin Wei, Liping Zhang, Chao Wang, Zefeng Li, Mingjie Luo, Guomin Xie, Xingjiu Yang, Mengyuan Li, Shuyue Ren, Dongbing Zhao^*, Ran Gao^*, Jia-Nan Gong* Anti-apoptotic protein BCL-XL as a therapeutic vulnerability in gastric cancer. Animal Model Exp Med. 2023;6(3):245-254.

5. Ming?Jie Luo, Michelle Palmieri, Chris D Riffkin, Anuratha Sakthianandeswaren, Tirta Mario Djajawi, Yumiko Hirokawa, Victoria Shuttleworth, David H Segal, Christine A White, Duong Nhu, Guillaume Lessene, Margaret Lee, Peter Gibbs, David CS Huang^*, Oliver M Sieber^* and Jia-Nan Gong^*. Define the susceptibility of colorectal cancers to BH3 mimetic compounds. Cell Death & Disease. 2020;11(9):735. (IF:8.469)

6. Piers Blombery^#, Mary Ann Anderson^#, Jia-nan Gong^#, Rachel Thijssen^#, Richard W.Birkinshaw^#, Ella Thompson, Charis E. Teh, Tamia Nguyen, Zhen Xu, Christoffer Flensburg, Thomas E. Lew, Ian J. Majewski, Daniel H.D. Gray, David A. Westerman, Constantine S. Tam, John F. Seymour, Peter E. Czabotar, David C.S. Huang, Andrew W. Roberts. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discovery. 2019;9(3):342-353. (C100; IF:26.37）)

7. Jia-nan Gong^#, Tiffany Khong, David Segal, Yuan Yao, Chris D. Riffkin, Jean-Marc Garnier, Seong Lin Khaw, Guillaume Lessene, Andrew Spencer, Marco J. Herold, Andrew W. Roberts, David C. S. Huang. Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. Blood. 2016;128(14):1834-1844. (Cover story; C100; IF：13.164)

8. Gong JN^#, Yu J^#, Lin HS^#, Zhang XH, Yin XL, Xiao Z, Wang F, Wang XS, Su R, Shen C, Zhao HL, Ma YN, Zhang JW. The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia. Cell Death Differ. 2014;21(1):100-12. (C100; IF:8.184)

9. Jia-nan Gong^#, Jianxiong Li^#, Yi Wang^#, Changzheng Liu^#, Hongyan Jia, Chongliang Jiang, Yuxuan Wang, Min Luo, Hongmei Zhao, Lei Dong, Fang Wang, Junwu Zhang, Jia Yu. Characterization of microRNA-29 family expression and investigation of their mechanistic and therapeutic roles in gastric cancer. Carcinogenesis. 2014; 35(2):497-506. (C100; IF:4.004)

10. Xiao-Shuang Wang^#, Jia-Nan Gong^#, Jia Yu, Fang Wang, Xin-Hua Zhang, Xiao-Lin Yin, Zhen-Qing Tan, Zi-Mian Luo, Gui-Hua Yang, Chao Shen, Jun-Wu Zhang. MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia. Blood. 2012; 119:4992 -5004. (C100; ESI; IF:9.06）